UCARTCS1A is an allogeneic (donor-derived) CAR T-cell therapy being developed for multiple myeloma patients.
| SparkCures ID | 338 |
|---|---|
| Developed By | Cellectis S.A. |
| Generic Name | UCARTCS1A |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.